肝脏 ›› 2026, Vol. 31 ›› Issue (5): 678-686.

• 代谢相关脂肪性肝病 • 上一篇    下一篇

基于MMC平台构建2型糖尿病合并非酒精性脂肪性肝病ASCVD风险预测模型及应用

鄂雪玲, 蔡若男, 火焱, 黄希红, 陈张哲   

  1. 221000 徐州 徐州医科大学研究生院(鄂雪玲);
    221000 徐州 徐州市第一人民医院(徐州医科大学附属徐州市立医院)(蔡若男,火焱,黄希红,陈张哲)
  • 收稿日期:2025-06-25 发布日期:2026-07-10
  • 通讯作者: 火焱,Email:of2ev7@163.com
  • 基金资助:
    徐州市卫生健康委医学科技创新面上项目(XWKYHT20220103)

Risk prediction model of ASCVD for type 2 diabetes mellitus with nonalcoholic fatty liver disease constructed based on MMC platform and its application

E Xue-ling1, CAI Ruo-nan2, HUO Yan2, HUANG Xi-hong2, CHEN Zhang-zhe2   

  1. 1. Graduate School, Xuzhou Medical University, Xuzhou 221000, China;
    2. Department of Endocrinology, Xuzhou First People’s Hospital (the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University), Xuzhou 221000, China
  • Received:2025-06-25 Published:2026-07-10
  • Contact: HUO Yan,Email:of2ev7@163.com

摘要: 目的 基于国家标准化代谢性疾病管理中心(MMC)平台构建2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者发生动脉粥样硬化性心血管疾病(ASCVD)的风险预测模型。方法 回顾性分析2021年9月至2024年1月徐州市第一人民医院MMC平台中记录的391例T2DM合并NAFLD患者的临床资料,根据7∶3比例随机分为训练组(274例)与验证组(117例),自出院当天经MMC平台持续随访至2024年8月。根据随访期间有无并发ASCVD将训练组分为ASCVD组、无ASCVD组,比较2组临床资料;采用Cox回归法分析ASCVD的影响因素,计算回归系数、标准误、风险比(HR)及95%置信区间(95%CI),并基于影响因素构建T2DM合并NAFLD患者发生ASCVD的风险预测列线图模型。基于训练组与验证组的数据,采用受试者工作特征(ROC)曲线、Hosmer-Lemeshow拟合优度分析分别验证模型的预测效能及校准度,采用决策曲线分析法(DCA)评估模型的临床获益情况。结果 随访6~42个月,中位数22(10,35)个月;训练组ASCVD发生率为31.02%(85/274),验证组ASCVD发生率为30.77%(36/117),总发生率为30.95%(121/391);尿微量白蛋白/肌酐比(UACR)(HR=2.328,95%CI:1.498~3.618)、血浆致动脉粥样硬化指数(AIP)(HR=2.237,95%CI:1.505~3.323)、甘油三酯-葡萄糖-体质指数(TyG-BMI)(HR=2.787,95%CI:1.626~4.778)、弗雷明汉风险评分系统(FRS)(HR=2.497,95%CI:1.376~4.531)、内脏/皮下脂肪面积比(VSR)(HR=2.809,95%CI:1.564~5.048)及脉搏波传导速度(PWV)(HR=3.050,95%CI:1.619~5.744)是发生ASCVD的危险因素(P<0.05),肾小球滤过率估计值(eGFR)(HR=0.396,95%CI:0.262~0.599)是发生ASCVD的保护因素(P<0.05);基于以上7个影响因素构建T2DM合并NAFLD患者发生ASCVD的风险预测列线图模型;该模型预测验证组及训练组发生ASCVD的ROC曲线下面积分别为0.959(95%CI:0.929~0.980)、0.890(95%CI:0.819~0.941),灵敏度分别为87.06%、83.33%,特异度分别为93.65%、92.59%;该模型对验证组及训练组发生ASCVD的预测概率与实际概率比较,差异无统计学意义(P>0.05);该模型预测验证组及训练组发生ASCVD的阈值概率分别为0.05~0.87、0.04~0.85时可获得临床净收益。结论 基于MMC平台发现,UACR、AIP、TyG-BMI、FRS、VSR及PWV是T2DM合并NAFLD患者发生ASCVD的危险因素,eGFR则是保护因素,基于这些影响因素构建风险预测列线图模型对ASCVD的预测价值高。

关键词: 2型糖尿病, 非酒精性脂肪性肝病, 动脉粥样硬化性心血管疾病, 国家标准化代谢性疾病管理中心

Abstract: Objective To constructed risk prediction model of arteriosclerotic cardiovascular disease (ASCVD) for type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD) based on national metabolic management center (MMC). Methods The clinical data of 391 T2DM patients with NAFLD recorded in the MMC platform of Xuzhou First People′s Hospital from September 2021 to January 2024 were retrospectively analyzed, they were randomly divided into training group (274 cases) and verification group (117 cases) according to a 7∶3 ratio. They were continuously followed up on the MMC platform continued to following up from the day of discharge to August 2024. The training group was divided into ASCVD group and ASCVD group according to the presence or absence of ASCVD during the following up period, the clinical data of the 2 groups were compared, and Cox regression method was used to analyze the influencing factors of ASCVD. Regression coefficient, standard error, hazard ratio (HR) and 95% confidence interval (95%CI) were calculated. Based on the influencing factors, the risk prediction nomogram model of ASCVD in T2DM patients with NAFLD was constructed. Based on the data from the training and validation groups, the receiver operating characteristic (ROC) curve and Hosmer-Lemeshow goodness of fit analysis were used to verify the prediction efficiency and calibration degree of the model, and decision curve analysis (DCA) was used to evaluate the clinical benefit of the model. Results The following-up period was ranged from 6 to 42 months, with a median of 22 (10,35) months. The incidence of ASCVD was 31.02% (85/274) in the training group, 30.77% (36/117) in the verification group, and 30.95% (121/391) in the overall incidence. Urinary albumin to creatinine ratio (UACR) (HR=2.328, 95%CI: 1.498~3.618), atherogenic index of plasma (AIP) (HR=2.237, 95%CI: 1.505~3.323), triglyceride glucose-body mass index (TyG-BMI) (HR=2.787, 95%CI: 1.626~4.778), framingham risk score (FRS) (HR=2.497, 95%CI: 1.376~4.531), visceral-to-subcutaneous fat ratio (VSR) (HR=2.809, 95%CI: 1.564~5.048) and pulse wave velocity (PWV) (HR=3.050, 95%CI: 1.619~5.744) were the risk factors of ASCVD (P<0.05), and estimated glomerular filtration rate (eGFR) (HR=0.396, 95%CI: 0.262~0.599) was the protective factors for ASCVD (P<0.05). Based on the above 7 influencing factors, the risk prediction model of ASCVD in T2DM patients with NAFLD was constructed. The area under ROC curve for predicting ASCVD in the verification group and the training group were 0.959 (95%CI: 0.929~0.980) and 0.890 (95%CI: 0.819~0.941), the sensitivity were 87.06% and 83.33%, and the specificity were 93.65% and 92.59%. There was no significant difference between the predicted probability of ASCVD and the actual probability in the verification group and the training group (P>0.05). The model predicted that the threshold probability of ASCVD in the validation group and the training group was 0.05~0.87 and 0.04~0.85. Conclusion Based on the discovery from the MMC platform discovery, UACR, AIP, TyG-BMI, FRS, VSR and PWV are risk factors for ASCVD in T2DM patients with NAFLD, while eGFR is a protective factor, the risk prediction nomogram model based on these influencing factors has high predictive value for ASCVD.

Key words: Type 2 diabetes mellitus, Nonalcoholic fatty liver disease, Atherosclerotic cardiovascular disease, National metabolic management center